{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:44:16Z","timestamp":1793245456242,"version":"4.5.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1038\/s41581-022-00630-8","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T12:10:22Z","timestamp":1664280622000},"page":"794-805","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-9675","authenticated-orcid":false,"given":"Ben","family":"Sprangers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7875-090X","authenticated-orcid":false,"given":"David E.","family":"Leaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2412-1563","authenticated-orcid":false,"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3621-0766","authenticated-orcid":false,"given":"Maria Jos\u00e9","family":"Soler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Perazella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"630_CR1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nature10755","volume":"482","author":"H Matsushita","year":"2012","unstructured":"Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400\u2013404 (2012).","journal-title":"Nature"},{"key":"630_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nm.3161","volume":"19","author":"PF Robbins","year":"2013","unstructured":"Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747\u2013752 (2013).","journal-title":"Nat. Med."},{"key":"630_CR3","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","volume":"31","author":"N van Rooij","year":"2013","unstructured":"van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439\u2013e442 (2013).","journal-title":"J. Clin. Oncol."},{"key":"630_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"630_CR5","doi-asserted-by":"publisher","first-page":"15074","DOI":"10.1073\/pnas.96.26.15074","volume":"96","author":"ED Kwon","year":"1999","unstructured":"Kwon, E. D. et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl Acad. Sci. USA 96, 15074\u201315079 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"630_CR6","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","volume":"114","author":"M Ahmadzadeh","year":"2009","unstructured":"Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537\u20131544 (2009).","journal-title":"Blood"},{"key":"630_CR7","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","volume":"363","author":"C Xu","year":"2018","unstructured":"Xu, C. et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 363, k4226 (2018).","journal-title":"BMJ"},{"key":"630_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158\u2013168 (2018).","journal-title":"N. Engl. J. Med."},{"key":"630_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat, S. et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann. Oncol. 27, 559\u2013574 (2016).","journal-title":"Ann. Oncol."},{"key":"630_CR10","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja, L., Day, D., Wei-Wu, C. T., Siu, L. L. & Hansen, A. R. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann. Oncol. 28, 2377\u20132385 (2017).","journal-title":"Ann. Oncol."},{"key":"630_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"N. Engl. J. Med."},{"key":"630_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.10.017","volume":"107","author":"Y Kanjanapan","year":"2019","unstructured":"Kanjanapan, Y. et al. Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. Eur. J. Cancer 107, 1\u20137 (2019).","journal-title":"Eur. J. Cancer"},{"key":"630_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2215\/CJN.03530412","volume":"8","author":"AK Salahudeen","year":"2013","unstructured":"Salahudeen, A. K. et al. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin. J. Am. Soc. Nephrol. 8, 347\u2013354 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"630_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.34067\/KID.0000152019","volume":"1","author":"S Manohar","year":"2020","unstructured":"Manohar, S. et al. Acute interstitial nephritis and checkpoint inhibitor therapy. Kidney360 1, 16\u201324 (2020).","journal-title":"Kidney360"},{"key":"630_CR15","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.ekir.2020.07.011","volume":"5","author":"H Seethapathy","year":"2020","unstructured":"Seethapathy, H. et al. Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors. Kidney Int. Rep. 5, 1700\u20131705 (2020).","journal-title":"Kidney Int. Rep."},{"key":"630_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/CJI.0000000000000338","volume":"44","author":"JD Sorah","year":"2021","unstructured":"Sorah, J. D., Rose, T. L., Radhakrishna, R., Derebail, V. K. & Milowsky, M. I. Incidence and prediction of immune checkpoint inhibitor-related nephrotoxicity. J. Immunother. 44, 127\u2013131 (2021).","journal-title":"J. Immunother."},{"key":"630_CR17","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/CJN.00990119","volume":"14","author":"H Seethapathy","year":"2019","unstructured":"Seethapathy, H. et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin. J. Am. Soc. Nephrol. 14, 1692\u20131700 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"630_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000467","volume":"8","author":"A Meraz-Munoz","year":"2020","unstructured":"Meraz-Munoz, A. et al. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J. Immunother. Cancer 8, e000467 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"630_CR19","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/ndt\/gfaa137","volume":"36","author":"C Stein","year":"2021","unstructured":"Stein, C. et al. Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrol. Dial. Transplant. 36, 1664\u20131674 (2021).","journal-title":"Nephrol. Dial. Transplant."},{"key":"630_CR20","first-page":"887","volume":"37","author":"C Garc\u00eda-Carro","year":"2022","unstructured":"Garc\u00eda-Carro, C. et al. Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrol. Dial. Transplant. 37, 887\u2013894 (2022).","journal-title":"Nephrol. Dial. Transplant."},{"key":"630_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ndt\/gfy105","volume":"34","author":"S Manohar","year":"2019","unstructured":"Manohar, S. et al. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol. Dial. Transpl. 34, 108\u2013117 (2019).","journal-title":"Nephrol. Dial. Transpl."},{"key":"630_CR22","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar, F. B. et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90, 638\u2013647 (2016).","journal-title":"Kidney Int"},{"key":"630_CR23","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","volume":"35","author":"M Sznol","year":"2017","unstructured":"Sznol, M. et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J. Clin. Oncol. 35, 3815\u20133822 (2017).","journal-title":"J. Clin. Oncol."},{"key":"630_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo, R. et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am. J. Nephrol. 45, 160\u2013169 (2017).","journal-title":"Am. J. Nephrol."},{"key":"630_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003467","author":"S Gupta","year":"2021","unstructured":"Gupta, S. et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-003467 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"630_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"630_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing, K. et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271\u2013275 (2008).","journal-title":"Science"},{"key":"630_CR28","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","volume":"25","author":"A Sharma","year":"2019","unstructured":"Sharma, A. et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clin. Cancer Res 25, 1233\u20131238 (2019).","journal-title":"Clin. Cancer Res"},{"key":"630_CR29","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711\u2013723 (2010).","journal-title":"N. Engl. J. Med."},{"key":"630_CR30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320\u2013330 (2015).","journal-title":"N. Engl. J. Med."},{"key":"630_CR31","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J., Hodi, F. S. & Wolchok, J. D. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 1270\u20131271 (2015).","journal-title":"N. Engl. J. Med."},{"key":"630_CR32","doi-asserted-by":"publisher","first-page":"7466","DOI":"10.4049\/jimmunol.179.11.7466","volume":"179","author":"J Menke","year":"2007","unstructured":"Menke, J. et al. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J. Immunol. 179, 7466\u20137477 (2007).","journal-title":"J. Immunol."},{"key":"630_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141\u2013151 (1999).","journal-title":"Immunity"},{"key":"630_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319\u2013322 (2001).","journal-title":"Science"},{"key":"630_CR35","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/nm955","volume":"9","author":"T Okazaki","year":"2003","unstructured":"Okazaki, T. et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9, 1477\u20131483 (2003).","journal-title":"Nat. Med."},{"key":"630_CR36","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541\u2013547 (1995).","journal-title":"Immunity"},{"key":"630_CR37","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","volume":"270","author":"P Waterhouse","year":"1995","unstructured":"Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985\u2013988 (1995).","journal-title":"Science"},{"key":"630_CR38","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/sj.ejhg.5201214","volume":"12","author":"M Barreto","year":"2004","unstructured":"Barreto, M. et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur. J. Hum. Genet. 12, 620\u2013626 (2004).","journal-title":"Eur. J. Hum. Genet."},{"key":"630_CR39","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/rheumatology\/41.2.180","volume":"41","author":"B Vaidya","year":"2002","unstructured":"Vaidya, B. et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology 41, 180\u2013183 (2002).","journal-title":"Rheumatology"},{"key":"630_CR40","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature01621","volume":"423","author":"H Ueda","year":"2003","unstructured":"Ueda, H. et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506\u2013511 (2003).","journal-title":"Nature"},{"key":"630_CR41","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/ng1020","volume":"32","author":"L Prokunina","year":"2002","unstructured":"Prokunina, L. et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 32, 666\u2013669 (2002).","journal-title":"Nat. Genet."},{"key":"630_CR42","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1093\/rheumatology\/ker211","volume":"50","author":"C-H Huang","year":"2011","unstructured":"Huang, C.-H. et al. Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis. Rheumatology 50, 1809\u20131813 (2011).","journal-title":"Rheumatology"},{"key":"630_CR43","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros, C. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13, 473\u2013486 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"630_CR44","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/cncr.31043","volume":"124","author":"RN Pillai","year":"2018","unstructured":"Pillai, R. N. et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer 124, 271\u2013277 (2018).","journal-title":"Cancer"},{"key":"630_CR45","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3389\/fphar.2019.01300","volume":"10","author":"H Xu","year":"2019","unstructured":"Xu, H. et al. Antitumor activity and treatment-related toxicity associated with nivolumab plus ipilimumab in advanced malignancies: a systematic review and meta-analysis. Front. Pharmacol. 10, 1300 (2019).","journal-title":"Front. Pharmacol."},{"key":"630_CR46","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41591-021-01623-z","volume":"28","author":"AX Lozano","year":"2022","unstructured":"Lozano, A. X. et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat. Med. 28, 353\u2013362 (2022).","journal-title":"Nat. Med."},{"key":"630_CR47","doi-asserted-by":"publisher","first-page":"11919","DOI":"10.1073\/pnas.1611421113","volume":"113","author":"SK Subudhi","year":"2016","unstructured":"Subudhi, S. K. et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc. Natl Acad. Sci. USA 113, 11919\u201311924 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"630_CR48","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749\u20131755 (2016).","journal-title":"N. Engl. J. Med."},{"key":"630_CR49","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.clim.2005.01.005","volume":"115","author":"H Ding","year":"2005","unstructured":"Ding, H., Wu, X. & Gao, W. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. Clin. Immunol. 115, 184\u2013191 (2005).","journal-title":"Clin. Immunol."},{"key":"630_CR50","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1093\/ndt\/gfh423","volume":"19","author":"R Schoop","year":"2004","unstructured":"Schoop, R. et al. Suppressed T-cell activation by IFN-\u03b3-induced expression of PD-L1 on renal tubular epithelial cells. Nephrol. Dial. Transplant. 19, 2713\u20132720 (2004).","journal-title":"Nephrol. Dial. Transplant."},{"key":"630_CR51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/ki.2010.97","volume":"78","author":"A Starke","year":"2010","unstructured":"Starke, A. et al. Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses. Kidney Int 78, 38\u201347 (2010).","journal-title":"Kidney Int"},{"key":"630_CR52","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4049\/jimmunol.1400497","volume":"194","author":"K Jaworska","year":"2015","unstructured":"Jaworska, K. et al. Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J. Immunol. 194, 325\u2013333 (2015).","journal-title":"J. Immunol."},{"key":"630_CR53","doi-asserted-by":"publisher","first-page":"624547","DOI":"10.3389\/fimmu.2020.624547","volume":"11","author":"S Hakroush","year":"2020","unstructured":"Hakroush, S. et al. Variable expression of programmed cell death protein 1-ligand 1 in kidneys independent of immune checkpoint inhibition. Front. Immunol. 11, 624547 (2020).","journal-title":"Front. Immunol."},{"key":"630_CR54","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1681\/ASN.2019070676","volume":"31","author":"FB Cortazar","year":"2020","unstructured":"Cortazar, F. B. et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J. Am. Soc. Nephrol. 31, 435\u2013446 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"630_CR55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12882-018-0848-y","volume":"19","author":"R Koda","year":"2018","unstructured":"Koda, R. et al. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report. BMC Nephrol. 19, 48 (2018).","journal-title":"BMC Nephrol."},{"key":"630_CR56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/CJI.0000000000000236","volume":"42","author":"F Dimitriou","year":"2019","unstructured":"Dimitriou, F. et al. Cytokine release syndrome during sequential treatment with immune checkpoint inhibitors and kinase inhibitors for metastatic melanoma. J. Immunother. 42, 29\u201332 (2019).","journal-title":"J. Immunother."},{"key":"630_CR57","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fmed.2018.00351","volume":"5","author":"JA Bridge","year":"2018","unstructured":"Bridge, J. A., Lee, J. C., Daud, A., Wells, J. W. & Bluestone, J. A. Cytokines, chemokines, and other biomarkers of response for checkpoint inhibitor therapy in skin cancer. Front. Med. 5, 351 (2018).","journal-title":"Front. Med."},{"key":"630_CR58","doi-asserted-by":"publisher","first-page":"840313","DOI":"10.3389\/fimmu.2022.840313","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang, H. et al. Interleukin-10 is a promising marker for immune-related adverse events in patients with non-small cell lung cancer receiving immunotherapy. Front. Immunol. 13, 840313 (2022).","journal-title":"Front. Immunol."},{"key":"630_CR59","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2022.04.004","volume":"40","author":"Y Hailemichael","year":"2022","unstructured":"Hailemichael, Y. et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40, 509\u2013523.e506 (2022).","journal-title":"Cancer Cell"},{"key":"630_CR60","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMc0904283","volume":"361","author":"F Fadel","year":"2009","unstructured":"Fadel, F., El Karoui, K. & Knebelmann, B. Anti-CTLA4 antibody-induced lupus nephritis. N. Engl. J. Med. 361, 211\u2013212 (2009).","journal-title":"N. Engl. J. Med."},{"key":"630_CR61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12882-016-0224-8","volume":"17","author":"DE Leaf","year":"2016","unstructured":"Leaf, D. E. Excessive diagnostic testing in acute kidney injury. BMC Nephrol. 17, 9 (2016).","journal-title":"BMC Nephrol."},{"key":"630_CR62","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2215\/CJN.01330213","volume":"8","author":"AK Muriithi","year":"2013","unstructured":"Muriithi, A. K., Nasr, S. H. & Leung, N. Utility of urine eosinophils in the diagnosis of acute interstitial nephritis. Clin. J. Am. Soc. Nephrol. 8, 1857\u20131862 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"630_CR63","first-page":"66","volume":"6","author":"A Kitchlu","year":"2020","unstructured":"Kitchlu, A. et al. A systematic review of checkpoint inhibitor-associated glomerular disease. KI Rep. 6, 66\u201377 (2020).","journal-title":"KI Rep."},{"key":"630_CR64","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073\u20134126 (2021).","journal-title":"J. Clin. Oncol."},{"key":"630_CR65","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","volume":"17","author":"JA Thompson","year":"2019","unstructured":"Thompson, J. A. et al. Management of immunotherapy-related toxicities, version 1.2019. J. Natl Compr. Canc. Netw. 17, 255\u2013289 (2019).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"630_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer, J. R. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J. Immunother. Cancer 9, e002435 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"630_CR67","unstructured":"Thompson, J. et al. NCCN Guidelines Version 1.2022: Management of Immunotherapy-Related Toxicities. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1486 (2022)."},{"key":"630_CR68","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"J Haanen","year":"2017","unstructured":"Haanen, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28, iv119\u2013iv142 (2017).","journal-title":"Ann. Oncol."},{"key":"630_CR69","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/ckj\/sfaa008","volume":"14","author":"D Oleas","year":"2021","unstructured":"Oleas, D. et al. Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. Clin. Kidney J. 14, 1364\u20131370 (2021).","journal-title":"Clin. Kidney J."},{"key":"630_CR70","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac177","author":"S Andrulli","year":"2022","unstructured":"Andrulli, S. et al. The risks associated with percutaneous native kidney biopsies: a prospective study. Nephrol. Dial. Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfac177 (2022).","journal-title":"Nephrol. Dial. Transplant."},{"key":"630_CR71","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s40425-019-0820-9","volume":"7","author":"D Qualls","year":"2019","unstructured":"Qualls, D. et al. Positron emission tomography as an adjuvant diagnostic test in the evaluation of checkpoint inhibitor-associated acute interstitial nephritis. J. Immunother. Cancer 7, 356 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"630_CR72","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002292","volume":"9","author":"MD Lee","year":"2021","unstructured":"Lee, M. D. et al. Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. J. Immunother. Cancer 9, e002292 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"630_CR73","doi-asserted-by":"publisher","first-page":"j1415","DOI":"10.1136\/bmj.j1415","volume":"357","author":"AK Waljee","year":"2017","unstructured":"Waljee, A. K. et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 357, j1415 (2017).","journal-title":"BMJ"},{"key":"630_CR74","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/jcpt.13469","volume":"46","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J. Clin. Pharm. Ther. 46, 927\u2013935 (2021).","journal-title":"J. Clin. Pharm. Ther."},{"key":"630_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004421","author":"ML Baker","year":"2022","unstructured":"Baker, M. L. et al. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-004421 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"630_CR76","doi-asserted-by":"publisher","first-page":"1877415","DOI":"10.1080\/2162402X.2021.1877415","volume":"10","author":"JS Lin","year":"2021","unstructured":"Lin, J. S. et al. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology 10, 1877415 (2021).","journal-title":"Oncoimmunology"},{"key":"630_CR77","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejca.2021.08.031","volume":"157","author":"F Dimitriou","year":"2021","unstructured":"Dimitriou, F., Hogan, S., Menzies, A. M., Dummer, R. & Long, G. V. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. Eur. J. Cancer 157, 214\u2013224 (2021).","journal-title":"Eur. J. Cancer"},{"key":"630_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001622","volume":"8","author":"M Allouchery","year":"2020","unstructured":"Allouchery, M. et al. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade \u22652 immune-related adverse events in patients with cancer. J. Immunother. Cancer 8, e001622 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"630_CR79","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2215\/CJN.02340219","volume":"14","author":"MA Perazella","year":"2019","unstructured":"Perazella, M. A. & Sprangers, B. AKI in patients receiving immune checkpoint inhibitors. Clin. J. Am. Soc. Nephrol. 14, 1077\u20131079 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"630_CR80","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","volume":"7","author":"O Mamlouk","year":"2019","unstructured":"Mamlouk, O. et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J. Immunother. Cancer 7, 2 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"630_CR81","doi-asserted-by":"publisher","first-page":"1927313","DOI":"10.1080\/2162402X.2021.1927313","volume":"10","author":"M Abdelahim","year":"2021","unstructured":"Abdelahim, M. et al. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis. Oncoimmunology 10, 1927313 (2021).","journal-title":"Oncoimmunology"},{"key":"630_CR82","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1681\/ASN.2018050488","volume":"29","author":"MA Perazella","year":"2018","unstructured":"Perazella, M. A. & Shirali, A. C. Nephrotoxicity of cancer immunotherapies: past, present and future. J. Am. Soc. Nephrol. 29, 2039\u20132052 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"630_CR83","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","volume":"100","author":"N Murakami","year":"2021","unstructured":"Murakami, N. et al. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 100, 196\u2013205 (2021).","journal-title":"Kidney Int."},{"key":"630_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00368-0","author":"RP Carroll","year":"2022","unstructured":"Carroll, R. P. et al. Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study. Lancet Oncol. https:\/\/doi.org\/10.1016\/s1470-2045(22)00368-0 (2022).","journal-title":"Lancet Oncol."},{"key":"630_CR85","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/ckj\/sfab090","volume":"14","author":"A Kitchlu","year":"2021","unstructured":"Kitchlu, A., Jhaveri, K. D., Sprangers, B., Yanagita, M. & Wanchoo, R. Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review. Clin. Kidney J. 14, 2012\u20132022 (2021).","journal-title":"Clin. Kidney J."},{"key":"630_CR86","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.ajkd.2021.05.012","volume":"79","author":"DF Chute","year":"2022","unstructured":"Chute, D. F. et al. Incidence and predictors of CKD and estimated GFR decline in patients receiving immune checkpoint inhibitors. Am. J. Kidney Dis. 79, 134\u2013137 (2022).","journal-title":"Am. J. Kidney Dis."},{"key":"630_CR87","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","volume":"6","author":"B Isik","year":"2021","unstructured":"Isik, B. et al. Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events. Kidney Int. Rep. 6, 1022\u20131031 (2021).","journal-title":"Kidney Int. Rep."},{"key":"630_CR88","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127456","volume":"4","author":"DG Moledina","year":"2019","unstructured":"Moledina, D. G. et al. Urine TNF-\u03b1 and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight 4, e127456 (2019).","journal-title":"JCI Insight"},{"key":"630_CR89","first-page":"112","volume":"4","author":"C Heybeli","year":"2020","unstructured":"Heybeli, C., Nathan, M. A. & Herrmann, S. Renal injury in the setting of immune checkpoint inhibitor: report of a case of hypothyroidism and the role of positron emission tomography. J. Onconephrol. 4, 112\u2013116 (2020).","journal-title":"J. Onconephrol."},{"key":"630_CR90","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.xkme.2020.05.015","volume":"2","author":"SM Herrmann","year":"2020","unstructured":"Herrmann, S. M., Alexander, M. P., Romero, M. F. & Zand, L. Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor-a report of 3 cases. Kidney Med. 2, 657\u2013662 (2020).","journal-title":"Kidney Med."},{"key":"630_CR91","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000505235","volume":"13","author":"S Okawa","year":"2020","unstructured":"Okawa, S. et al. Rapidly progressive acute kidney injury associated with nivolumab treatment. Case Rep. Oncol. 13, 85\u201390 (2020).","journal-title":"Case Rep. Oncol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00630-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00630-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00630-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T14:04:15Z","timestamp":1668607455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-022-00630-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":91,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1038\/s41581-022-00630-8","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"assertion":[{"value":"24 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}